Halozyme Therapeutics (HALO) EPS (Basic) Growth (3y) (2013 - 2026)
Halozyme Therapeutics (HALO) EPS (Basic) Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 6.85% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 11.71% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 64.84% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 37.21% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.99% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | -38.31% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 36.73% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.51% |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 51.17% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 51.17% |
| Mar 31, 2026 | 62.98% |
| Dec 31, 2025 | -68.71% |
| Sep 30, 2025 | 49.06% |
| Jun 30, 2025 | 102.28% |
| Mar 31, 2025 | 29.96% |
| Dec 31, 2024 | 31.53% |
| Sep 30, 2024 | -10.86% |
| Jun 30, 2024 | 4.55% |
| Mar 31, 2024 | 44.11% |
| Dec 31, 2023 | 6.41% |
| Sep 30, 2023 | 32.75% |
| Jun 30, 2023 | 44.03% |
| Mar 31, 2023 | 104.84% |
| Dec 31, 2022 | 55.63% |
| Sep 30, 2022 | 66.76% |
| Jun 30, 2022 | 53.76% |
| Mar 31, 2022 | 227.70% |
| Dec 31, 2021 | 224.17% |
| Sep 30, 2021 | 114.60% |